BmooMPα-I has
kininogenase activity, cleaving
kininogen releasing
bradykinin and can hydrolyze
angiotensin I at post-
proline and
aspartic acid positions, generating an inactive
peptide. We evaluated the
antihypertensive activity of BmooMPα-I in a model of two-kidney, one-
clip (2K1C). Wistar rats were divided into groups:
Sham, who underwent
sham surgery, and 2K1C, who suffered
stenosis of the right renal artery. In the second week of
hypertension, we started treatment (Vehicle, BmooMPα-I and
Losartan) for two weeks. We performed an electrocardiogram and blood and heart collection in the fourth week of
hypertension. The 2K1C BmooMPα-I showed a reduction in blood pressure (systolic pressure: 131 ± 2 mmHg; diastolic pressure: 84 ± 2 mmHg versus 174 ± 3 mmHg; 97 ± 4 mmHg, 2K1C Vehicle, p < 0.05), improvement in electrocardiographic parameters (Heart Rate: 297 ± 4 bpm; QRS: 42 ± 0.1 ms; QT: 92 ± 1 ms versus 332 ± 6 bpm; 48 ± 0.2 ms; 122 ± 1 ms, 2K1C Vehicle, p < 0.05), without changing the hematological profile (platelets: 758 ± 67; leukocytes: 3980 ± 326 versus 758 ± 75; 4400 ± 800, 2K1C Vehicle, p > 0.05), with reversal of
hypertrophy (left ventricular area: 12.1 ± 0.3; left ventricle wall thickness: 2.5 ± 0.2; septum wall thickness: 2.3 ± 0.06 versus 10.5 ± 0.3; 2.7 ± 0.2; 2.5 ± 0.04, 2K1C Vehicle, p < 0.05) and
fibrosis (3.9 ± 0.2 versus 7.4 ± 0.7, 2K1C Vehicle, p < 0.05). We concluded that BmooMPα-I improved blood pressure levels and cardiac remodeling, having a cardioprotective effect.